Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review
Rattachement africain : gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: Anti-synthetase syndrome (ASS) is a chronic autoimmune condition, with interstitial lung disease (ILD) being a key feature. This systematic literature review (SLR; CRD42023416414) aimed to summarize treatments and outcomes of ILD associated with ASS (ASS-ILD). METHODS: Databases were searched for articles discussing ASS-ILD management and outcomes, published 1946-September 2023. Screening and data extraction were performed by two reviewers. Meta-analysis, using a random effects model, and paired t-tests were undertaken where appropriate to evaluate post-treatment-change in pulmonary function tests. RESULTS: Ten articles were included, comprising 514 patients: 67.8% female, mean age 52.4 years (s.d. 4.6). Baseline high-resolution CT was documented in 447 patients (86.9%); the most common pattern was non-specific interstitial pneumonia (n = 220; 49.2%). The most common myositis-associated autoantibody was anti-Jo1 (48%), with 27.8% having associated anti-Ro52 antibodies. Pooled estimate, after meta-analysis, for baseline forced vital capacity (FVC) was 60.8% predicted (s.e. 2.1) and for diffusion capacity of lungs for carbon monoxide (DLco) was 49.8% (s.e. 3.5). After 1 year, pooled improvement in FVC was 14.1% from baseline (s.e. 3.1) and in DLco was 15.1% (s.e. 2.8). Paired t-test demonstrated significant overall improvement in FVC (P = 0.007) and DLco (P = 0.002). Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1 year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively. Twenty-eight deaths were reported. CONCLUSION: Our SLR, the first to summarize management and outcomes of ASS-ILD, found no conclusive difference between effectiveness of treatments. More robust trials are required to reduce morbidity and mortality resulting from ASS-ILD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review
- Date Crossref
- 31/07/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Liverpool pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Lewisham Department of Rheumatology pays non établi dans la noticeÉtablissement de santé
-
King's College - North Carolina pays non établi dans la noticeUniversité ou école supérieure
-
King's College London pays non établi dans la noticeUniversité ou école supérieure
-
British Medical Association pays non établi dans la noticeOrganisme public
-
Aintree University Hospitals NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
Liverpool Womens NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Kings’ College London Centre for Rheumatic Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Liverpool University NHS Foundation Trust Aintree Hospital pays non établi dans la noticeUniversité ou école supérieure
University of Liverpool, Department of Rheumatology — University Hospital Lewisham et King's College - North Carolina, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.